Announcements Trials
Browse Landscape

Phase

Phase 1 7Phase 2 6Phase 3 3Phase NA 1Phase 2/3 1Phase 1/2 1

Status

Active not recruiting 2Recruiting 1

Sponsor Class

OTHER 8INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Thoracic 1Plasma cell 1Gynecologic 1

Conditions

Ovarian Neoplasms 1Multiple Myeloma 1Fallopian Tube Neoplasms 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Carboplatin 315Paclitaxel 303Cisplatin 250Docetaxel 238pembrolizumab 230Gemcitabine 214Pemetrexed 158Capecitabine 147Rituximab 144Bevacizumab 142Dexamethasone 125Fluorouracil 121Cyclophosphamide 102Trastuzumab 100Doxorubicin 96Nivolumab 93Prednisone 92Oxaliplatin 90atezolizumab 75Leucovorin 72durvalumab 69130-nm albumin-bound paclitaxel 68Injections 66Lenalidomide 63Irinotecan 62Bortezomib 56Letrozole 54Topotecan 53Fulvestrant 53Drug Therapy 50

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 3 × INDUSTRY × Acetaminophen × Clear all
NCT06305754 2026-05-29

MK-2870-009

Merck Sharp & Dohme LLC

Phase 3 Active not recruiting
520 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT06824467 2026-05-29

TroFuse-022

Merck Sharp & Dohme LLC

Phase 3 Recruiting
770 enrolled
Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT04270409 2025-12-12

Isatuximab in Combination With Lenalidomide and Dexamethasone in High-risk Smoldering Multiple Myeloma

Sanofi

Phase 3 Active not recruiting
337 enrolled
Plasma cell

Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡